# Human Reference Data Collection Methodology

## Overview

This document outlines the methodology for collecting human reference data to enable signature matching between human psychopharmacological responses and model neuromodulation effects. The data will be used for canonical correlation analysis and validation of the neuromodulation pack system.

## Study Design

### **Double-Blind, Placebo-Controlled, Randomized Crossover Design**

- **Participants**: N=120 healthy adults (18-65 years)
- **Study Duration**: 8 weeks (1 week per condition + washout)
- **Conditions**: 6 active conditions + 1 placebo control
- **Randomization**: Latin square design with balanced allocation
- **Blinding**: Double-blind (participant and assessor)

## Substances and Dosages

### **Active Conditions**

| Substance | Dosage | Route | Timing | Rationale |
|-----------|--------|-------|--------|-----------|
| **Caffeine** | 200mg | Oral | T+0 | Stimulant reference, focus enhancement |
| **L-Theanine** | 200mg | Oral | T+0 | Relaxation, anxiety reduction |
| **Modafinil** | 100mg | Oral | T+0 | Wakefulness, cognitive enhancement |
| **LSD** | 100μg | Oral | T+0 | Psychedelic, creativity enhancement |
| **MDMA** | 75mg | Oral | T+0 | Empathogen, social enhancement |
| **THC** | 10mg | Oral | T+0 | Cannabis, relaxation/creativity |

### **Control Condition**

| Substance | Dosage | Route | Timing | Rationale |
|-----------|--------|-------|--------|-----------|
| **Placebo** | 0mg | Oral | T+0 | Control for expectancy effects |

### **Safety Considerations**

- **Medical Screening**: Comprehensive health assessment
- **Contraindications**: Exclude participants with psychiatric history, cardiovascular conditions
- **Monitoring**: Continuous vital signs, adverse event reporting
- **Emergency Protocol**: 24/7 medical supervision, emergency contacts
- **Ethics Approval**: IRB approval, informed consent

## Data Collection Timeline

### **Pre-Study (Week -1)**
- **T-7 days**: Screening, baseline assessments
- **T-3 days**: Training on assessment tools
- **T-1 day**: Final eligibility confirmation

### **Study Sessions (Weeks 1-8)**
- **T-60 min**: Pre-dose baseline assessments
- **T+0**: Substance administration
- **T+30 min**: Early effects assessment
- **T+60 min**: Peak effects assessment
- **T+120 min**: Sustained effects assessment
- **T+240 min**: Late effects assessment
- **T+480 min**: End-of-day assessment

### **Post-Study (Week 9)**
- **T+7 days**: Follow-up safety assessment
- **T+14 days**: Final data collection

## Assessment Instruments

### **Primary Psychometric Measures**

#### **1. Altered States of Consciousness Scale (ASCS)**
- **Purpose**: Measure altered states of consciousness
- **Items**: 94 items across 11 subscales
- **Timing**: T+60, T+120, T+240
- **Scoring**: 0-5 Likert scale

#### **2. State Dissociation Questionnaire (SDQ)**
- **Purpose**: Measure dissociative states
- **Items**: 21 items across 3 subscales
- **Timing**: T+60, T+120, T+240
- **Scoring**: 0-4 Likert scale

#### **3. Profile of Mood States (POMS)**
- **Purpose**: Measure mood states
- **Items**: 65 items across 6 subscales
- **Timing**: T+30, T+60, T+120, T+240
- **Scoring**: 0-4 Likert scale

#### **4. Creative Achievement Questionnaire (CAQ)**
- **Purpose**: Measure creative thinking
- **Items**: 96 items across 10 domains
- **Timing**: T+60, T+120
- **Scoring**: 0-7 Likert scale

### **Secondary Cognitive Measures**

#### **1. Digit Span Task**
- **Purpose**: Working memory assessment
- **Timing**: T+60, T+120
- **Scoring**: Forward and backward span

#### **2. Stroop Color-Word Test**
- **Purpose**: Attention and cognitive control
- **Timing**: T+60, T+120
- **Scoring**: Reaction time and accuracy

#### **3. Remote Associates Test (RAT)**
- **Purpose**: Creative problem-solving
- **Timing**: T+60, T+120
- **Scoring**: Number of correct associations

#### **4. Trail Making Test**
- **Purpose**: Executive function and attention
- **Timing**: T+60, T+120
- **Scoring**: Completion time

### **Physiological Measures**

#### **1. Heart Rate Variability (HRV)**
- **Purpose**: Autonomic nervous system activity
- **Timing**: Continuous monitoring
- **Scoring**: RMSSD, pNN50, LF/HF ratio

#### **2. Blood Pressure**
- **Purpose**: Cardiovascular monitoring
- **Timing**: Every 30 minutes
- **Scoring**: Systolic and diastolic pressure

#### **3. Body Temperature**
- **Purpose**: Thermoregulation monitoring
- **Timing**: Every 60 minutes
- **Scoring**: Core body temperature

## Data Collection Procedures

### **Standardized Administration**

1. **Environment**: Controlled laboratory setting
2. **Lighting**: Consistent ambient lighting
3. **Temperature**: 20-22°C maintained
4. **Noise**: Minimal background noise
5. **Equipment**: Standardized computers/tablets

### **Assessment Protocol**

1. **Pre-Assessment**: Brief orientation and practice
2. **Assessment**: Standardized instructions and timing
3. **Post-Assessment**: Debriefing and clarification
4. **Data Entry**: Real-time entry with validation

### **Quality Control**

1. **Training**: All assessors trained and certified
2. **Calibration**: Regular equipment calibration
3. **Monitoring**: Random quality checks
4. **Documentation**: Detailed procedure logs

## Data Management

### **Data Collection Forms**

- **Participant Information Sheet**: Demographics, medical history
- **Substance Administration Log**: Dosage, timing, adverse events
- **Assessment Worksheets**: Standardized response forms
- **Physiological Data Log**: Continuous monitoring records

### **Data Entry and Validation**

- **Real-time Entry**: Immediate data entry during sessions
- **Double Entry**: 10% random sample double-entered
- **Validation Rules**: Automated data quality checks
- **Error Correction**: Documented correction procedures

### **Data Storage and Security**

- **Encryption**: All data encrypted at rest and in transit
- **Access Control**: Role-based access permissions
- **Backup**: Daily automated backups
- **Retention**: 7-year retention policy

## Statistical Analysis Plan

### **Primary Analyses**

1. **Descriptive Statistics**: Mean, SD, range for all measures
2. **Repeated Measures ANOVA**: Within-subject effects across time
3. **Post-hoc Comparisons**: Pairwise comparisons between conditions
4. **Effect Size Calculations**: Cohen's d for all comparisons

### **Signature Matching**

1. **Canonical Correlation Analysis**: Human vs. model signatures
2. **Factor Analysis**: Dimensionality reduction
3. **Cluster Analysis**: Grouping of similar responses
4. **Machine Learning**: Predictive modeling

### **Power Analysis**

- **Target Effect Size**: d = 0.5 (medium effect)
- **Power**: 0.80
- **Alpha**: 0.05
- **Required N**: 120 participants
- **Dropout Rate**: 15% (N=140 enrolled)

## Ethical Considerations

### **Informed Consent**

- **Comprehensive Information**: Full disclosure of risks and benefits
- **Voluntary Participation**: No coercion or undue influence
- **Right to Withdraw**: Can withdraw at any time without penalty
- **Data Use**: Clear explanation of data usage and sharing

### **Risk Management**

- **Medical Supervision**: Licensed physician present
- **Emergency Protocols**: Clear emergency response procedures
- **Adverse Event Reporting**: Immediate reporting and follow-up
- **Insurance Coverage**: Comprehensive liability insurance

### **Data Privacy**

- **Anonymization**: Personal identifiers removed
- **Confidentiality**: Strict confidentiality protocols
- **Data Sharing**: Controlled access for research purposes
- **Right to Know**: Participants can request their data

## Budget and Resources

### **Personnel**

- **Principal Investigator**: 1.0 FTE
- **Study Coordinator**: 1.0 FTE
- **Research Assistants**: 4.0 FTE
- **Medical Supervisor**: 0.5 FTE
- **Data Manager**: 0.5 FTE

### **Equipment and Supplies**

- **Assessment Tools**: Standardized software and hardware
- **Physiological Monitoring**: HRV, BP, temperature devices
- **Data Management**: Secure database and backup systems
- **Substances**: Pharmaceutical-grade compounds
- **Safety Equipment**: Emergency response equipment

### **Estimated Costs**

- **Personnel**: $500,000
- **Equipment**: $100,000
- **Supplies**: $50,000
- **Substances**: $25,000
- **Overhead**: $100,000
- **Total**: $775,000

## Timeline

### **Phase 1: Preparation (Months 1-3)**
- IRB approval and regulatory compliance
- Staff training and certification
- Equipment procurement and setup
- Participant recruitment

### **Phase 2: Data Collection (Months 4-11)**
- Screening and enrollment
- Study sessions (8 weeks per participant)
- Data collection and quality control
- Safety monitoring

### **Phase 3: Analysis (Months 12-15)**
- Data cleaning and validation
- Statistical analysis
- Signature matching analysis
- Report preparation

## Deliverables

### **Data Products**

1. **Raw Data**: Complete dataset with all measures
2. **Processed Data**: Cleaned and validated dataset
3. **Signature Matrices**: Human response signatures
4. **Comparison Data**: Human vs. model correlations

### **Documentation**

1. **Study Protocol**: Detailed methodology
2. **Data Dictionary**: Variable definitions and coding
3. **Analysis Code**: Statistical analysis scripts
4. **Results Report**: Comprehensive findings

### **Publications**

1. **Primary Paper**: Human reference data collection
2. **Secondary Paper**: Signature matching methodology
3. **Method Paper**: Data collection procedures
4. **Open Data**: Public dataset release

## Contact Information

**Principal Investigator**: [Name, Title, Institution]
**Email**: [email@institution.edu]
**Phone**: [phone number]
**Address**: [institution address]

**Study Coordinator**: [Name, Title]
**Email**: [coordinator@institution.edu]
**Phone**: [phone number]

**Medical Supervisor**: [Name, MD]
**Email**: [medical@institution.edu]
**Phone**: [phone number]

---

*This document serves as the comprehensive methodology for human reference data collection. All procedures must be approved by the Institutional Review Board (IRB) and conducted in accordance with ethical guidelines and regulatory requirements.*
